Drug Detail
Information about Binimetinib
Generic Name |
Binimetinib | |
|---|---|---|
IND |
MEK162 | |
Brand Name (US) |
||
Manufacturer |
Novartis | |
Drug Type |
||
Delivery |
Oral | |
Approval Status |
Phase 3 | |
Indications |
||
Overall Strategy |
Oncogenic Signal Path Based | |
Strategy |
Block KIT Signal Path | |
Drug Category |
MEK inhibitor | |
Links |
|
|
Novartis pipeline |
|
Combined inhibition of MAP kinase and KIT signaling effectively destabilizes the ETV1 protein and synergistically suppresses GIST tumorigenesis |
Trials of this drug |
|
Trial results |
|
Search for this drug/combination in: